NPC-01 clinical trials
Also written NPC-01.
How each study uses NPC-01 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses NPC-01 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female VolunteersCompletedPhase 3NobelpharmaNCT01246791Written as NPC-01
- Efficacy and Safety, Long-Term Study of NPC-01 to Treat Dysmenorrhea Associated With EndometriosisCompletedPhase 3NobelpharmaNCT00902746Written as NPC-01
- Pharmacodynamics of NPC-01/IKH-01; Effect of NPC-01/IKH-01 on Sexual Hormone Concentrations in Healthy Female VolunteersCompletedPhase 3NobelpharmaNCT01253824Written as NPC-01
- Efficacy and Safety Study of NPC-01 to Treat DysmenorrheaCompletedPhase 3NobelpharmaNCT01129102Written as NPC-01